Compare Aegon Ltd. (AEG) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs Bristol-Myers Squibb Co — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while Bristol-Myers Squibb Co trades at $57.94 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.1× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (5.3%). Which is the better fit depends on your goals.
| AEG | BMY | |
|---|---|---|
Market Cap | $12.98B | $118.38B |
Sector | Financials | Health |
52-Week High | $8.79 | $62.37 |
52-Week Low | $6.79 | $42.60 |
Enterprise Value | $14.11B | $154.32B |
Dividend Yield | 5.3% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
